# Ipamorelin Safe

> An authored reading of what the ipamorelin literature actually says about safety — and what it doesn't. Editorial reading of the 1998 Raun selectivity characterization, the 1999 Gobburu PK/PD work in eight male volunteers per dose group, the 2014 Beck Phase 2 trial in 114 postoperative bowel-resection patients (P=0.15, missed primary endpoint), the 2024 FDA PCAC briefing (aggregation, immunogenicity, unnatural amino acid impurity concerns; serious adverse event including death on the record), and the gray-market product-quality risk that arguably eclipses the molecule's intrinsic pharmacology. No chronic human safety data exists. Not approved by FDA, EMA, or any other major regulator. WADA-prohibited at all times under S2.2.4. Independent editorial project; not a clinic, not a pharmacy, not a vendor.

## Pages

- [Overview](https://ipamorelinsafe.com/index.md): An authored reading of the ipamorelin safety record — one short Phase 2 trial, FDA aggregation and immunogenicity concerns, no chronic human data, and a gray-market supply that flunks the basics.
- [Research](https://ipamorelinsafe.com/research.md): Page-by-page editorial walk through the ipamorelin literature: 1998 selectivity, 1999 human PK/PD, 2014 Phase 2, 2024 FDA review, and the chronic-exposure questions that remain open.
- [Dosage](https://ipamorelinsafe.com/dosage.md): Doses that have actually appeared in published rodent and human ipamorelin protocols, with half-life, routes, and the chronic-exposure gap clearly drawn. Research context only — not a dosing recommendation.
- [FAQ](https://ipamorelinsafe.com/faq.md): Direct, cited answers to the recurring questions about ipamorelin safety: Phase 2 adverse events, the FDA 2024 review, the chronic-exposure gap, glycemic effects, gray-market product quality, GHRP-6/GHRP-2 comparison, WADA status.
- [References](https://ipamorelinsafe.com/references.md): Numbered citation list with DOIs and PubMed links for all 18 ipamorelin studies referenced on this site.
- [About](https://ipamorelinsafe.com/about.md): Editorial standards, scope, sourcing methodology. Not a clinic, not a pharmacy, not a vendor.
- [Contact](https://ipamorelinsafe.com/contact.md): Editorial corrections, citation requests, fact-check notes, and feedback. No medical questions, no dosing guidance, no vendor referrals.

## Reading conventions

Inline citations use [N] markers linking to the references page. Every HTML page has a Markdown sibling at the same path with a .md suffix. Append .md to any URL to fetch the markdown alternate, or send Accept: text/markdown. See also: https://ipamorelinsafe.com/llms-full.txt for the entire site concatenated as markdown.